Apheresis
Apheresis is an intervention with 26 clinical trials. Currently 5 active trials ongoing. Historical success rate of 76.5%.
Success Metrics
Based on 13 completed trials
Phase Distribution
Phase Distribution
9
Early Stage
13
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
65.0%
13 of 20 finished
35.0%
7 ended early
5
trials recruiting
26
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma
Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder
Ex Vivo Expansion (ACT-X)
Stem Cell Transplantation for Patients With Multiple Myeloma
Clinical Trials (26)
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma
Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder
Ex Vivo Expansion (ACT-X)
Stem Cell Transplantation for Patients With Multiple Myeloma
A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
APACA-Apheresis/acoustophoresis and Molecular Characterization of Prostate Cancer
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
Development of Immune Globulin Treatment for Avian Flu
Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Collection of Transplant Stem Cells for Plasma Cell Myeloma
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Granulocyte-monocyte Apheresis in Ulcerative Colitis
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 26